Doroshow J - Search Results

1

3-Deazaguanine: report of a phase I trial and drug-related cardiac toxicity.

Margolin K, Doroshow J, Leong L, Akman S, Carr B, Odujinrin O, Flanagan B, Grove W, DeLap R, Goldberg D. Margolin K, et al. Among authors: doroshow j. Invest New Drugs. 1990 Nov;8(4):369-76. doi: 10.1007/BF00198593. Invest New Drugs. 1990. PMID: 2084070 Clinical Trial.

2

DNA base modifications induced in isolated human chromatin by NADH dehydrogenase-catalyzed reduction of doxorubicin.

Akman SA, Doroshow JH, Burke TG, Dizdaroglu M. Akman SA, et al. Among authors: doroshow jh. Biochemistry. 1992 Apr 7;31(13):3500-6. doi: 10.1021/bi00128a026. Biochemistry. 1992. PMID: 1313297

3

Phase II trial of piroxantrone in advanced non-small cell carcinoma of the lung. A Southwest Oncology Group study.

Williamson SK, Crowley JJ, Livingston R, Hantel A, Doroshow JH. Williamson SK, et al. Among authors: doroshow jh. Invest New Drugs. 1992 Apr;10(1):29-30. doi: 10.1007/BF01275476. Invest New Drugs. 1992. PMID: 1318871 Clinical Trial. No abstract available.

4

Phase II trial of cisplatin and alpha-interferon in advanced malignant melanoma.

Margolin KA, Doroshow JH, Akman SA, Leong LA, Morgan RJ, Somlo G, Raschko J, Pereira C, Yonemoto L, Ahn C. Margolin KA, et al. Among authors: doroshow jh. J Clin Oncol. 1992 Oct;10(10):1574-8. doi: 10.1200/JCO.1992.10.10.1574. J Clin Oncol. 1992. PMID: 1403037 Clinical Trial.

5

Copper-dependent site-specific mutagenesis by benzoyl peroxide in the supF gene of the mutation reporter plasmid pS189.

Akman SA, Doroshow JH, Kensler TW. Akman SA, et al. Among authors: doroshow jh. Carcinogenesis. 1992 Oct;13(10):1783-7. doi: 10.1093/carcin/13.10.1783. Carcinogenesis. 1992. PMID: 1423838

6

Phase II trial of 5-fluorouracil, high-dose leucovorin calcium, and dipyridamole in advanced prostate cancer.

Singh D, Doroshow JH, Leong L, Margolin K, Akman S, Raschko J, Somlo G, Morgan R, Harrison J, Cho J, et al. Singh D, et al. Among authors: doroshow jh. J Cancer Res Clin Oncol. 1992;119(2):117-20. doi: 10.1007/BF01209667. J Cancer Res Clin Oncol. 1992. PMID: 1429827 Clinical Trial.

7

A phase II trial of CI-921 in advanced malignancies.

Sklarin NT, Wiernik PH, Grove WR, Benson L, Mittelman A, Maroun JA, Stewart JA, Robert F, Doroshow JH, Rosen PJ, et al. Sklarin NT, et al. Among authors: doroshow jh. Invest New Drugs. 1992 Nov;10(4):309-12. doi: 10.1007/BF00944186. Invest New Drugs. 1992. PMID: 1487405 Clinical Trial.

8

Pharmacokinetics and toxicity of continuous infusion (6S)-folinic acid and bolus 5-fluorouracil in patients with advanced cancer.

Newman EM, Akman SA, Harrison JS, Leong LA, Margolin KA, Morgan RJ, Raschko JW, Somlo G, Ahn CW, Doroshow JH. Newman EM, et al. Among authors: doroshow jh. Cancer Res. 1992 May 1;52(9):2408-12. Cancer Res. 1992. PMID: 1568210 Clinical Trial.

9

Effective initial therapy of advanced breast cancer with fluorouracil and high-dose, continuous infusion calcium leucovorin.

Margolin KA, Doroshow JH, Akman SA, Leong LA, Morgan RJ, Raschko JW, Somlo G, Blevins C. Margolin KA, et al. Among authors: doroshow jh. J Clin Oncol. 1992 Aug;10(8):1278-83. doi: 10.1200/JCO.1992.10.8.1278. J Clin Oncol. 1992. PMID: 1634917

10

A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma.

Weiss GR, Margolin KA, Aronson FR, Sznol M, Atkins MB, Dutcher JP, Gaynor ER, Boldt DH, Doroshow JH, Bar MH, et al. Weiss GR, et al. Among authors: doroshow jh. J Clin Oncol. 1992 Feb;10(2):275-81. doi: 10.1200/JCO.1992.10.2.275. J Clin Oncol. 1992. PMID: 1732429 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

506 results

Search Page

Filters